latest news releases from the newsroom
Sunnylife Global, Inc.
Retired California State Senator Richard Polanco Headed the Delegation to Hebei, China for the Turnover Ceremony of the Hebei World Friendship Hospital to Sunnylife Global, Inc.
LOS ANGELES, Aug. 13, 2007 (PRIME NEWSWIRE) -- Sunnylife Global, Inc. (Pink Sheets:SNYL) announced today that California State Senator Richard Polanco (Ret.), Special Advisor to Sunnylife for almost two years, headed up the Delegation to Hebei China for the Turnover Ceremony on August 9, 2007 of the Hebei World Friendship Hospital to Sunnylife Global, Inc.
Avantair Retains The Piacente Group as Strategic Investor Relations Consulting Firm
CLEARWATER, Fla., Aug. 13, 2007 (PRIME NEWSWIRE) -- Avantair, Inc. (OTCBB:AAIR) (OTCBB:AAIRU) (OTCBB:AAIRW), the only publicly traded stand-alone fractional operator, today announced that it has retained The Piacente Group, a full service investor relations consulting firm based in New York. The Piacente Group will assist Avantair in implementing investor communications and Wall Street outreach programs aimed at introducing the financial community to the Company.
Avigen Initiates U.S. Clinical Development for AV411
ALAMEDA, Calif., Aug. 13, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company developing innovative therapies for the treatment of chronic neurological conditions, today announced it received approval from the U.S. Food and Drug Administration (FDA) to proceed with the U.S. clinical development of AV411 (ibudilast). The initial U.S. clinical trial for AV411, which is treated as a New Chemical Entity in the United States, will be a Phase I maximum tolerated dose study that is designed to build on data from Avigen's Phase I and exploratory Phase IIa studies in Australia. This larger U.S. Phase I trial is designed to assess the safety and tolerability of AV411. This trial is also intended to assess the effect of food on AV411 pharmacokinetics and tolerability. In parallel, Avigen's Australian Phase IIa trial is expected to provide safety and initial efficacy data of AV411 in patients with neuropathic pain and is expected to report by the end of 2007.
Foundry Networks, Inc.
GameRail Gives Online Gamers the Competitive Edge by Deploying Foundry Backbone Routers
SANTA CLARA, Calif. and ST. LOUIS, Aug. 13, 2007 (PRIME NEWSWIRE) -- Foundry Networks(r), Inc. (Nasdaq:FDRY), a performance and total solutions leader for end-to-end switching and routing, today announced that GameRail installed Foundry Networks' NetIron(r) XMR 4000 multi-service backbone routers to power North America's only high performance and low latency private online gaming network targeting serious members of the Web gaming community. Leveraging the NetIron XMR's performance and robust MultiProtocol Label Switching (MPLS) capabilities, GameRail is able to offer an affordable paid subscription service that offers fewer routing hops, increased response times and considerably lower latency to gamers than those using the public Internet exclusively.
SWsoft Announces First Half Growth, New Milestones Reached
HERNDON, Va., Aug. 13, 2007 (PRIME NEWSWIRE) -- Driven by growing acceptance of its Parallels virtual machine software and Virtuozzo operating system (OS) virtualization software, SWsoft today announced that its revenues grew by 127 percent for the first half of 2007 versus the first half of 2006.